Celldex Therapeutics reported $182.28M in Equity Capital and Reserves for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Equity Capital And Reserves Change
Agenus AGEN:US $ -228.84M 61.78M
Amgen AMGN:US $ 8247M 1087M
Applied Genetic Technologies AGTC:US $ 85.81M 11.19M
Aptinyx Inc APTX:US $ 130.76M 18.18M
Arena Pharmaceuticals ARNA:US $ 971.08M 114.91M
Biocept BIOC:US $ 29.35M 2.58M
Bristol Myers Squibb BMY:US $ 36808M 797M
Celldex Therapeutics CLDX:US $ 182.28M 11.88M
Cytrx CYTR:US 6.49M 1.1M
Glaxosmithkline GSK:US $ 15377M 512M
Immunogen IMGN:US $ 68.46M 25.66M
Merrimack Pharmaceuticals MACK:US $ 16.01M 734K
Nektar Therapeutics NKTR:US $ 904.98M 89.53M
Newlink Genetics NLNK:US $ 101.12M 7.85M
Northwest Biotherapeutics NWBO:US -349842000 3.36M
Rigel Pharmaceuticals RIGL:US $ 68.11M 10.19M
Seattle Genetics SGEN:US $ 3391.27M 33.35M